28th Jun 2007 07:04
Deltex Medical Group PLC28 June 2007 Deltex Medical Group plc International endorsement of CardioQTM for critically ill children 28 June 2007 - Deltex Medical Group plc ("Deltex Medical" or "Company"), theUK's leading haemodynamic monitoring company, today announces new clinicalevidence of the value of its CardioQPTM monitoring system for the treatment ofyoung children in intensive care units. The results of four studies using CardioQP in hospitals in France, the UK andBrazil were presented this week to international doctors at the 5th WorldCongress on Paediatric Critical Care in Geneva, Switzerland. Doctors from the Hopital Arnaud de Villeneuve in Montpellier, France reportedthat they had found the CardioQP to be an excellent predictor of thefluid-responsiveness in children with low blood pressure. Paediatric intensive care specialists from Sao Paulo, Brazil concluded that theCardioQP "was extremely important in the evaluation and (management) of patientswith septic shock" particularly given "the limited forms of measuringhaemodynamic variables in paediatric intensive care units in low-incomecountries." A team from Birmingham Children's Hospital in the UK concluded in their study"that clinical assessment of cardiac output and systemic vascular resistance arefrequently unreliable" with doctors' own assessments agreeing with CardioQPmeasurements only approximately half the time. In a second study on 20 childrenin intensive care, the clinical management strategy was changed in eight of thenine cases where CardioQP data differed from the original clinical assessment. Deltex Medical's Chief Executive, Andy Hill commented: "These studies reinforce the strengths of the CardioQP in the monitoring andtreatment of very sick children. It is safe, accurate, affordable and easy touse: it allows doctors to assess childrens' haemodynamic status quickly and makebetter-informed clinical decisions. "This new clinical evidence supports further our belief that the CardioQP oughtto be made available to all doctors treating critically ill children." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman [email protected] Hill, Chief Executive [email protected] Phillips, Finance Director [email protected] Gavin Anderson & Company 020 7554 1400Deborah Walter [email protected] Speed [email protected] Charles Stanley Securities 020 7149 6457Philip Davies [email protected] Cook [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical